RxDoctor Payments Data

Ruben Reider, MD

Geriatric Medicine · Glen Burnie, MDNPI 1891890968

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2021 at $325 and has fallen 88.6% since, to $37 in 2025.

$1,093in general payments, 2019–2025

Across 35 payments — averaging $31.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$305
  • Nestle Healthcare Nutrition Inc.$292
  • Aimmune Therapeutics, Inc.$122
  • Novo Nordisk$111
  • Lilly USA, LLC$50
  • Amarin Pharma, Inc.$44
  • plus $170 from 7 others

What the payments were for

  • Food & beverage$1,093100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,093 in reported general payments places this provider in the 75th percentile of 112 geriatric medicine providers in Maryland.

See all geriatric medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$112,724
Medicare patients
156
Services billed
901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$76,869
EliquisApixaban43$52,169
TriumeqAbacavir/Dolutegravir/Lamivudi13$50,350
XareltoRivaroxaban22$32,725
JanuviaSitagliptin Phosphate13$19,658
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,888
Ezetimibe94$5,307
Losartan Potassium323$3,521
Tresiba Flextouch U-100Insulin Degludec11$3,491
Amlodipine Besylate327$2,570
Atorvastatin Calcium245$2,553
Pravastatin Sodium83$2,070
Metoprolol Succinate110$1,699
Rosuvastatin Calcium58$1,606
Albuterol Sulfate HfaAlbuterol Sulfate35$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$32$76,86949 claims
GSKTrelegy Ellipta$20$13,88817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 112 geriatric medicine providers in Maryland.

Other geriatric medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →